Pharma
Clinical trial recruitment is slow, expensive & imprecise. PULZ is designed to address all threex.
With $15.5B spent annually on clinical trial recruitment across 27,000 U.S. studies, the industry's leading research bottleneck is finding the right participants, fast enough, precisely enough, affordably enough. PULZ will enable access to a pre-consented, behavior-rich, longitudinally profiled population ready for matching. And once your trial is running, continuous live biometric data will close the gap between site visits — giving you a real-time window into participant behavior that no traditional RWD source can provide.
Up to 85% of clinical trials fail to recruit or retain a sufficient number of patients, and 80% of clinical trials still fail to meet enrollment timelines.
Key Benefits for Pharma, Life Sciences & Research Organizations
Richer, continuous, high-resolution real-world data
Traditional real-world data sources — EHR, claims, and registries — provide only static, episodic snapshots. PULZ adds the missing layer: continuous physiological and behavioral signals captured in real time from a pre-consented longitudinal population. This expands research beyond conventional datasets and aligns with leading real-world evidence frameworks.
Precision recruitment across all phases of research
PULZ accelerates recruitment across clinical and real-world research by enabling more precise cohort identification, AI-assisted pre-screening, faster enrollment, and lower screen-failure rates. Study design, execution, and oversight remain entirely with the sponsoring organization.
Post-market population intelligence and therapeutic optimization
Traditional post-market data is often retrospective and incomplete. PULZ adds continuous population-level insight into behavior, lifestyle, and physiology, helping sponsors understand real-world therapeutic performance and strengthen long-term evidence generation.
Precision therapeutics and digital biomarker discovery
PULZ brings EHR, genomics, wearables, and behavioral signals together in one consented platform, enabling richer risk modeling, digital biomarker development, and longitudinal phenotype insight, particularly in diseases shaped by lifestyle and behavior.
Become a Partner
